Last reviewed · How we verify
Analgesics, Non-Narcotic
At a glance
| Generic name | Analgesics, Non-Narcotic |
|---|---|
| Sponsor | Clinical Centre of Serbia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of TAP and QLB-1 Blocks on Opioid Consumption (NA)
- Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain (PHASE1)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
- Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis (NA)
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Analgesics, Non-Narcotic CI brief — competitive landscape report
- Analgesics, Non-Narcotic updates RSS · CI watch RSS
- Clinical Centre of Serbia portfolio CI